https://www.diabesityrounds.com/a/semaglutide-2-4-mg-in-obesity-related-hfpef-with-type-2-diabetes-phase-3-registrDiabesity Roundsen2026-11-02T20:02:53.042ZSemaglutide 2.4 mg in obesity-related HFpEF with type 2 diabetes: phase 3 registry resultshttps://www.diabesityrounds.com/a/next-generation-incretins-early-signals-beyond-semaglutide-not-yet-like-for-likeDiabesity Roundsen2026-11-01T02:03:18.256ZNext-generation incretins: early signals beyond semaglutide, not yet like for likehttps://www.diabesityrounds.com/a/lower-gdm-diagnostic-thresholds-doubled-diagnoses-without-better-short-term-outcDiabesity Roundsen2026-10-31T20:17:14.826ZLower GDM diagnostic thresholds doubled diagnoses without better short-term outcomes